Robert J. Lefkowitz, MD

Professor of Medicine
James B. Duke Distinguished Professor of Medicine
Professor of Biochemistry
Professor of Pathology
Professor of Chemistry
Associate of the Duke Initiative for Science & Society
Member of the Duke Cancer Institute
Campus mail 467 Clin & Res Labs, Durham, NC 27710
Phone (919) 684-2974
Email address

Dr. Lefkowitz’s memoir, A Funny Thing Happened on the Way to Stockholm, recounts his early career as a cardiologist and his transition to biochemistry, which led to his Nobel Prize win.

Robert J. Lefkowitz, M.D. is James B. Duke Professor of Medicine and Professor of Biochemistry and Chemistry at the Duke University Medical Center. He has been an Investigator of the Howard Hughes Medical Institute since 1976. Dr. Lefkowitz began his research career in the late 1960’s and early 1970’s when there was not a clear consensus that specific receptors for drugs and hormones even existed. His group spent 15 difficult years developing techniques for labeling the receptors with radioactive drugs and then purifying the four different receptors that were known and thought to exist for adrenaline, so called adrenergic receptors. In 1986 Dr. Lefkowitz transformed the understanding of what had by then become known as G protein coupled receptors because of the way the receptor signal for the inside of a cell through G proteins, when he and his colleagues cloned the gene for the beta2-adrenergic receptor. They immediately recognized the similarity to a molecule called rhodopsin which is essentially a light receptor in the retina. This unexpected finding established the beta receptor and rhodopsin as the first member of a new family of proteins. Because each has a peptide structure, which weaves across the cell membrane seven times, these receptors are referred to as seven transmembrane receptors. This super family is now known to be the largest, most diverse and most therapeutically accessible of all the different kinds of cellular receptors. There are almost a thousand members of this receptor family and they regulate virtually all known physiological processes in humans. They include the receptors not only to numerous hormones and neurotransmitters but for the receptors which mediate the senses of sweet and bitter taste and smell amongst many others. Dr. Lefkowitz also discovered the mechanism by which receptor signaling is turned off, a process known as desensitization. Dr. Lefkowitz work was performed at the most fundamental and basic end of the research spectrum and has had remarkable consequences for clinical medicine. Today, more than half of all prescription drug sales are of drugs that target either directly or indirectly the receptors discovered by Dr. Lefkowitz and his trainees. These include amongst many others beta blockers, angiotensin receptor blockers or ARBs and antihistamines. Over the past decade he has discovered novel mechanisms by which the receptors function which may lead to the development of an entirely new class of drugs called “biased agonists”. Several such compounds are already in advanced stages of clinical testing. Dr. Lefkowitz has received numerous honors and awards, including the National Medal of Science, the Shaw Prize, the Albany Prize, and the 2012 Nobel Prize in Chemistry. He was elected to the USA National Academy of Sciences in 1988, the Institute of Medicine in 1994, and the American Academy of Arts and Sciences in 1988.

Education and Training

  • Resident, Medicine, Massachusetts General Hospital, 1970 - 1971
  • Resident, Medicine, Columbia University, 1967 - 1968
  • Intern, Medicine, Columbia University, 1966 - 1967
  • M.D., Columbia University, 1966


Tang, Wei, Ryan T. Strachan, Robert J. Lefkowitz, and Howard A. Rockman. “Allosteric modulation of β-arrestin-biased angiotensin II type 1 receptor signaling by membrane stretch.” J Biol Chem 289, no. 41 (October 10, 2014): 28271–83.

Full Text

Shukla, Arun K., Gerwin H. Westfield, Kunhong Xiao, Rosana I. Reis, Li-Yin Huang, Prachi Tripathi-Shukla, Jiang Qian, et al. “Visualization of arrestin recruitment by a G-protein-coupled receptor.” Nature 512, no. 7513 (August 14, 2014): 218–22.

Full Text

Strachan, Ryan T., Jin-peng Sun, David H. Rominger, Jonathan D. Violin, Seungkirl Ahn, Alex Rojas Bie Thomsen, Xiao Zhu, Andrew Kleist, Tommaso Costa, and Robert J. Lefkowitz. “Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR).” J Biol Chem 289, no. 20 (May 16, 2014): 14211–24.

Full Text

Wisler, James, Emily Harris, Michael Raisch, Lan Mao, Jihee Kim, Howard Rockman, and Robert Lefkowitz. “NON-CANONICAL ANGIOTENSIN II TYPE 1A RECEPTOR-MEDIATED, BETA-ARRESTIN2-DEPENDENT SIGNALING CONTRIBUTES TO THORACIC AORTIC ANEURYSM FORMATION IN A MURINE MODEL OF MARFAN SYNDROME.” In Journal of the American College of Cardiology, 63:A2148–A2148. Elsevier BV, 2014.

Full Text

Staus, Dean P., Laura M. Wingler, Ryan T. Strachan, Soren G. F. Rasmussen, Els Pardon, Seungkirl Ahn, Jan Steyaert, Brian K. Kobilka, and Robert J. Lefkowitz. “Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies.” Mol Pharmacol 85, no. 3 (March 2014): 472–81.

Full Text

Rein, Lindsay A. M., Minyong Chen, Barbara S. Theriot, James W. Wisler, Laura M. Wingler, Richard T. Premont, Wei Chen, Julia K. L. Walker, and Robert J. Lefkowitz. “Targeting β-arrestin2 Enhances Survival in a Murine Model of Chronic Myeloid Leukemia.” In Blood, 122:857–857. American Society of Hematology, 2013.

Full Text

Simard, E., J. J. Kovacs, W. E. Miller, J. Kim, M. Grandbois, and R. J. Lefkowitz. “β-arrestin regulation of myosin light chain phosphorylation promotes AT1aR-mediated cell contraction and migration.” Plos One 8, no. 11 (November 8, 2013).

Full Text

Aristotelous, Tonia, Seungkirl Ahn, Arun K. Shukla, Sylwia Gawron, Maria F. Sassano, Alem W. Kahsai, Laura M. Wingler, et al. “Discovery of β2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor.” Acs Med Chem Lett 4, no. 10 (October 10, 2013): 1005–10.

Full Text